Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

1 to 15. (Canceled)

16. (Currently Amended) A method for inhibiting fusion between a membrane of a Hendra or Nipah virus and a plasma membrane of a cell comprising administering to a subject in need thereof a composition comprising an effective amount of at least one polypeptide sequence consisting of SEQ ID NO: 1 or SEQ ID NO: 2 and a pharmaceutically acceptable carrier.

17. (Previously Presented) The method of claim 16, wherein said virus is Nipah virus (NiV).

18. (Canceled)

19. (Previously Presented) The method of claim 16, wherein said virus is Hendra virus (HeV).

20 to 22. (Canceled)

23. (Currently Amended) A method for inducing an immune response to a Hendra or Nipah virus, comprising administering to a subject in need thereof a composition comprising an effective amount of at least one polypeptide sequence consisting of SEQ ID NO: 1 and SEQ ID NO: 2 and a pharmaceutically acceptable carrier.

24. (Previously Presented) The method of claim 23, wherein said virus is Nipah virus (NiV).

25. (Canceled)

26. (Currently Amended) The method of claim 23, wherein said virus is Hendra virus (HeV).

27 to 30. (Canceled)

31. (Currently Amended) A method of inducing an immune response to a Hendra or Nipah virus, comprising administering to a subject in need thereof a pharmaceutically effective amount of a composition comprising at least one polypeptide selected from the group consisting of:

(a) a polypeptide consisting of ~~comprising~~ SEQ ID NO: 1; and

(b) a polypeptide consisting of ~~comprising~~ SEQ ID NO: 2.

32 and 33. (Canceled)

34. (Previously Presented) The method of claim 31, wherein the method comprises administering a polypeptide consisting of SEQ ID NO: 1.

35. (Previously Presented) The method of claim 31, wherein the method comprises administering a polypeptide consisting of SEQ ID NO: 2.

36. (Previously Presented) The method of claim 31, wherein the subject is human.

37. (Previously Presented) The method of claim 31, wherein the composition further comprises a pharmaceutically acceptable carrier.

38. (Previously Presented) The method of claim 37, wherein the composition is formulated for oral administration, subcutaneous injection, intravenous injection, intramuscular injection, or intraperitoneal injection.

39. (Previously Presented) The method of claim 31, wherein the composition is formulated as an immunogenic composition.

40. (Previously Presented) The method of claim 31, wherein said virus is Nipah virus (NiV).

41. (Canceled)

42. (Previously Presented) The method of claim 31, wherein said virus is Hendra virus (HeV).

43 to 46. (Canceled)